Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436. 2022. View Article : Google Scholar : PubMed/NCBI

Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W and He J: Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2:1–9. 2022. View Article : Google Scholar : PubMed/NCBI

Bukowski K, Kciuk M and Kontek R: Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 21:32332020. View Article : Google Scholar : PubMed/NCBI

Xiao X, Wang K, Zong Q, Tu Y, Dong Y and Yuan Y: Polyprodrug with glutathione depletion and cascade drug activation for multi-drug resistance reversal. Biomaterials. 270:1206492021. View Article : Google Scholar : PubMed/NCBI

Bedard PL, Hyman DM, Davids MS and Siu LL: Small molecules, big impact: 20 Years of targeted therapy in oncology. Lancet. 395:1078–1088. 2020. View Article : Google Scholar : PubMed/NCBI

Li X, Li M, Huang M, Lin Q, Fang Q, Liu J, Chen X, Liu L, Zhan X, Shan H, et al: The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomed Pharmacother. 150:1130642022. View Article : Google Scholar : PubMed/NCBI

Phan TG and Croucher PI: The dormant cancer cell life cycle. Nat Rev Cancer. 20:398–411. 2020. View Article : Google Scholar : PubMed/NCBI

Chen X, Momin A, Wanggou S, Wang X, Min HK, Dou W, Gong Z, Chan J, Dong W, Fan JJ, et al: Mechanosensitive brain tumor cells construct blood-tumor barrier to mask chemosensitivity. Neuron. 111:30–48. e142023. View Article : Google Scholar : PubMed/NCBI

Inoue T, Aoyama-Ishikawa M, Uemura M, Kohama K, Fujisaki N, Murakami H, Yamada T and Hirata J: The role of death receptor signaling pathways in mouse Sertoli cell avoidance of apoptosis during LPS- and IL-18-induced inflammatory conditions. J Reprod Immunol. 158:1039702023. View Article : Google Scholar : PubMed/NCBI

Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, Bartolini A, Amodio V, Magrì A, Novara L, et al: Adaptive mutability of colorectal cancers in response to targeted therapies. Science. 366:1473–1480. 2019. View Article : Google Scholar : PubMed/NCBI

Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 486:537–540. 2012. View Article : Google Scholar : PubMed/NCBI

Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou M, Jin G, Rahman MM, McFadden G and Lu Y: Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell. 40:973–985.e7. 2022. View Article : Google Scholar : PubMed/NCBI

Hirota K, Ooka M, Shimizu N, Yamada K, Tsuda M, Ibrahim MA, Yamada S, Sasanuma H, Masutani M and Takeda S: XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. Genes Cells. 27:331–344. 2022. View Article : Google Scholar : PubMed/NCBI

Ovejero S, Soulet C and Moriel-Carretero M: The alkylating agent Methyl methanesulfonate triggers lipid alterations at the inner nuclear membrane that are independent from its DNA-damaging ability. Int J Mol Sci. 22:74612021. View Article : Google Scholar : PubMed/NCBI

Ghosh S: Cisplatin: The first metal based anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI

Fetoni AR, Paciello F and Troiani D: Cisplatin chemotherapy and cochlear damage: Otoprotective and chemosensitization properties of polyphenols. Antioxid Redox Signal. 36:1229–1245. 2022. View Article : Google Scholar : PubMed/NCBI

Curry JN and McCormick JA: Cisplatin-induced kidney injury: Delivering the goods. J Am Soc Nephrol. 33:255–256. 2022. View Article : Google Scholar : PubMed/NCBI

Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, et al: RX-3117 (fluorocyclopentenyl cytosine): A novel specific antimetabolite for selective cancer treatment. Expert Opin Investig Drugs. 28:311–322. 2019. View Article : Google Scholar : PubMed/NCBI

Guo J, Yu Z, Das M and Huang L: Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. Acs Nano. 14:5075–5089. 2020. View Article : Google Scholar : PubMed/NCBI

Li Z, Li C, Wu Q, Tu Y, Wang C, Yu X, Li B, Wang Z and Sun S and Sun S: MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway. Cell Death Dis. 12:972021. View Article : Google Scholar : PubMed/NCBI

Li J, Yu K, Pang D, Wang C, Jiang J, Yang S, Liu Y, Fu P, Sheng Y, Zhang G, et al: Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): An open-label, randomized, multicenter, phase III trial. J Clin Oncol. 38:1774–1784. 2020. View Article : Google Scholar : PubMed/NCBI

You JH, Lee J and Roh JL: PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells. J Exp Clin Cancer Res. 40:3502021. View Article : Google Scholar : PubMed/NCBI

Chen Y, Liu R, Li C, Song Y, Liu G, Huang Q, Yu L, Zhu D, Lu C, Lu A, et al: Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. Am J Cancer Res. 11:3445–3460. 2021.PubMed/NCBI

Elshamy AM, Salem OM, Safa MAE, Barhoma RAE, Eltabaa EF, Shalaby AM, Alabiad MA, Arakeeb HM and Mohamed HA: Possible protective effects of CO Q10 against vincristine-induced peripheral neuropathy: Targeting oxidative stress, inflammation, and sarmoptosis. J Biochem Mol Toxicol. 36:e229762022. View Article : Google Scholar : PubMed/NCBI

Rajković S, Živković MD and Djuran MI: Reactions of dinuclear Platinum(II) complexes with peptides. Curr Protein Pept Sci. 17:95–105. 2016. View Article : Google Scholar : PubMed/NCBI

Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II and Siddik ZH: Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 85:88–93. 2014. View Article : Google Scholar : PubMed/NCBI

Lv X, Song J, Xue K, Li Z, Li M, Zahid D, Cao H, Wang L, Song W, Ma T, et al: Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake. Mol Carcinog. 58:794–807. 2019. View Article : Google Scholar : PubMed/NCBI

Kalayda GV, Wagner CH and Jaehde U: Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem. 116:1–10. 2012. View Article : Google Scholar : PubMed/NCBI

Gao H, Zhang S, Hu T, Qu X, Zhai J, Zhang Y, Tao L, Yin J and Song Y: Omeprazole protects against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and transporter-mediated cisplatin accumulation in rats and HK-2 cells. Chem Biol Interact. 297:130–140. 2019. View Article : Google Scholar : PubMed/NCBI

Naka A, Takeda R, Shintani M, Ogane N, Kameda Y, Aoyama T, Yoshikawa T and Kamoshida S: Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer. Am J Cancer Res. 5:2285–2293. 2015.PubMed/NCBI

Hucke A, Rinschen MM, Bauer OB, Sperling M, Karst U, Köppen C, Sommer K, Schröter R, Ceresa C, Chiorazzi A, et al: An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection. Arch Toxicol. 93:2835–2848. 2019. View Article : Google Scholar : PubMed/NCBI

Verhalen B, Dastvan R, Thangapandian S, Peskova Y, Koteiche HA, Nakamoto RK, Tajkhorshid E and Mchaourab HS: Energy transduction and alternating access of the mammalian ABC transporter P-glycoprotein. Nature. 543:738–741. 2017. View Article : Google Scholar : PubMed/NCBI

Alam A, Kowal J, Broude E, Roninson I and Locher KP: Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science. 363:753–756. 2019. View Article : Google Scholar : PubMed/NCBI

Pasello M, Giudice AM and Scotlandi K: The ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer. Semin Cancer Biol. 60:57–71. 2020. View Article : Google Scholar : PubMed/NCBI

Hanssen KM, Haber M and Fletcher JI: Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. Drug Resist Updat. 59:1007952021. View Article : Google Scholar : PubMed/NCBI

Kim Y and Chen J: Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. Science. 359:915–919. 2018. View Article : Google Scholar : PubMed/NCBI

Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, et al: Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: A multicenter phase 2 trial. JAMA Oncol. 6:e2012502020. View Article : Google Scholar : PubMed/NCBI

Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE and Gottesman MM: Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018. View Article : Google Scholar : PubMed/NCBI

Carvalho DM, Richardson PJ, Olaciregui N, Stankunaite R, Lavarino C, Molinari V, Corley EA, Smith DP, Ruddle R, Donovan A, et al: Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer Discov. 12:416–431. 2022. View Article : Google Scholar : PubMed/NCBI

Cole SPC: Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future. Annu Rev Pharmacol Toxicol. 54:95–117. 2014. View Article : Google Scholar : PubMed/NCBI

Johnson ZL and Chen J: ATP binding enables substrate release from multidrug resistance protein 1. Cell. 172:81–89.e10. 2018. View Article : Google Scholar : PubMed/NCBI

Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R and Wildiers H: Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol. 24:1513–1525. 2013. View Article : Google Scholar : PubMed/NCBI

Cole SPC: Multidrug resistance protein 1 (MRP1, ABCC1), a ‘multitasking’ ATP-binding cassette (ABC) transporter. J Biol Chem. 289:30880–30888. 2014. View Article : Google Scholar : PubMed/NCBI

Taylor NMI, Manolaridis I, Jackson SM, Kowal J, Stahlberg H and Locher KP: Structure of the human multidrug transporter ABCG2. Nature. 546:504–509. 2017. View Article : Google Scholar : PubMed/NCBI

Kowal J, Ni D, Jackson SM, Manolaridis I, Stahlberg H and Locher KP: Structural basis of drug recognition by the multidrug transporter ABCG2. J Mol Biol. 433:1669802021. View Article : Google Scholar : PubMed/NCBI

Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X and Wu C: Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 277:1211102021. View Article : Google Scholar : PubMed/NCBI

Zhang J, Bai J, Zhou Q, Hu Y, Wang Q, Yang L, Chen H, An H, Zhou C, Wang Y, et al: Glutathione prevents high glucose-induced pancreatic fibrosis by suppressing pancreatic stellate cell activation via the ROS/TGFβ/SMAD pathway. Cell Death Dis. 13:4402022. View Article : Google Scholar : PubMed/NCBI

Chen M, Zhao S, Zhu J, Feng E, Lv F, Chen W, Lv S, Wu Y, Peng X and Song F: Open-source and reduced-expenditure nanosystem with ROS self-amplification and glutathione depletion for simultaneous augmented chemodynamic/photodynamic therapy. ACS Appl Mater Interfaces. 14:20682–20692. 2022. View Article : Google Scholar : PubMed/NCBI

Cheng X, Xu HD, Ran HH, Liang G and Wu FG: Glutathione-depleting nanomedicines for synergistic cancer therapy. ACS Nano. 15:8039–8068. 2021. View Article : Google Scholar : PubMed/NCBI

Gao P, Yang X, Xue YW, Zhang XF, Wang Y, Liu WJ and Wu XJ: Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. Cancer. 115:3222–3232. 2009. View Article : Google Scholar : PubMed/NCBI

Xu Y, Han X, Li Y, Min H, Zhao X, Zhang Y, Qi Y, Shi J, Qi S, Bao Y and Nie G: Sulforaphane mediates glutathione depletion via polymeric nanoparticles to restore cisplatin chemosensitivity. ACS Nano. 13:13445–13455. 2019. View Article : Google Scholar : PubMed/NCBI

Oshimori N, Oristian D and Fuchs E: TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell. 160:963–976. 2015. View Article : Google Scholar : PubMed/NCBI

Zhang KR, Zhang YF, Lei HM, Tang YB, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y, Chen HZ and Zhu L: Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci Transl Med. 13:eabg64282021. View Article : Google Scholar : PubMed/NCBI

Pang HH, Ke YC, Li NS, Chen YT, Huang CY, Wei KC and Yang HW: A new lateral flow plasmonic biosensor based on gold-viral biomineralized nanozyme for on-site intracellular glutathione detection to evaluate drug-resistance level. Biosens Bioelectron. 165:1123252020. View Article : Google Scholar : PubMed/NCBI

Harris IS, Endress JE, Coloff JL, Selfors LM, McBrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V, Oser MG, et al: Deubiquitinases maintain protein homeostasis and survival of cancer cells upon glutathione depletion. Cell Metab. 29:1166–1181.e6. 2019. View Article : Google Scholar : PubMed/NCBI

Stafford WC, Peng X, Olofsson MH, Zhang X, Luci DK, Lu L, Cheng Q, Trésaugues L, Dexheimer TS, Coussens NP, et al: Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med. 10:eaaf74442018. View Article : Google Scholar : PubMed/NCBI

Zhang X, Wang M, Feng J, Qin B, Zhang C, Zhu C, Liu W, Wang Y, Liu W, Huang L, et al: Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer. J Nanobiotechnology. 20:1662022. View Article : Google Scholar : PubMed/NCBI

Amort M, Nachbauer B, Tuzlak S, Kieser A, Schepers A, Villunger A and Polacek N: Expression of the vault RNA protects cells from undergoing apoptosis. Nat Commun. 6:70302015. View Article : Google Scholar : PubMed/NCBI

Liu S, Hao Q, Peng N, Yue X, Wang Y, Chen Y, Wu J and Zhu Y: Major vault protein: A virus-induced host factor against viral replication through the induction of type-I interferon. Hepatology. 56:57–66. 2012. View Article : Google Scholar : PubMed/NCBI

Bai H, Wang C, Qi Y, Xu J, Li N, Chen L, Jiang B, Zhu X, Zhang H, Li X, et al: Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway. BMC Cancer. 19:4542019. View Article : Google Scholar : PubMed/NCBI

Shen W, Qiu Y, Li J, Wu C, Liu Z, Zhang X, Hu X, Liao Y and Wang H: IL-25 promotes cisplatin resistance of lung cancer cells by activating NF-κB signaling pathway to increase of major vault protein. Cancer Med. 8:3491–3501. 2019. View Article : Google Scholar : PubMed/NCBI

Lou L, Wang J, Lv F, Wang G, Li Y, Xing L, Shen H and Zhang X: Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP). Cell Oncol (Dordr). 44:109–133. 2021. View Article : Google Scholar : PubMed/NCBI

Yu X, Liu W, Wang Z, Wang H, Liu J, Huang C, Zhao T, Wang X, Gao S, Ma Y, et al: CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Cancer Lett. 519:289–303. 2021. View Article : Google Scholar : PubMed/NCBI

Yu H, Li M, He R, Fang P, Wang Q, Yi Y, Wang F, Zhou L, Zhang Y, Chen A, et al: Major vault protein promotes hepatocellular carcinoma through targeting interferon regulatory factor 2 and decreasing p53 activity. Hepatology. 72:518–534. 2020. View Article : Google Scholar : PubMed/NCBI

Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI

Pilié PG, Tang C, Mills GB and Yap TA: State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 16:81–104. 2019. View Article : Google Scholar : PubMed/NCBI

Gourley C, Balmaña J, Ledermann JA, Serra V, Dent R, Loibl S, Pujade-Lauraine E and Boulton SJ: Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 37:2257–2269. 2019. View Article : Google Scholar : PubMed/NCBI

Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ and Lord CJ: Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10:1475–1488. 2020. View Article : Google Scholar : PubMed/NCBI

Ma J, Benitez JA, Li J, Miki S, Ponte de Albuquerque C, Galatro T, Orellana L, Zanca C, Reed R, Boyer A, et al: Inhibition of nuclear PTEN tyrosine phosphorylation enhances glioma radiation sensitivity through attenuated DNA repair. Cancer Cell. 35:504–518.e7. 2019. View Article : Google Scholar : PubMed/NCBI

Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, et al: Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 7:1006–1017. 2017. View Article : Google Scholar : PubMed/NCBI

Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, et al: Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat Cell Biol. 20:954–965. 2018. View Article : Google Scholar : PubMed/NCBI

Schlacher K: PARPi focus the spotlight on replication fork protection in cancer. Nat Cell Biol. 19:1309–1310. 2017. View Article : Google Scholar : PubMed/NCBI

Lord CJ and Ashworth A: Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 19:1381–1388. 2013. View Article : Google Scholar : PubMed/NCBI

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, et al: Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 535:382–387. 2016. View Article : Google Scholar : PubMed/NCBI

Awah CU, Chen L, Bansal M, Mahajan A, Winter J, Lad M, Warnke L, Gonzalez-Buendia E, Park C, Zhang D, et al: Ribosomal protein S11 influences glioma response to TOP2 poisons. Oncogene. 39:5068–5081. 2020. View Article : Google Scholar : PubMed/NCBI

Wang Z, Zhu Q, Li X, Ren X, Li J, Zhang Y, Zeng S, Xu L, Dong X and Zhai B: TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib. Am J Cancer Res. 12:4343–4360. 2022.PubMed/NCBI

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, et al: DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 373:1697–1708. 2015. View Article : Google Scholar : PubMed/NCBI

Mu Y, Lou J, Srivastava M, Zhao B, Feng XH, Liu T, Chen J and Huang J: SLFN11 inhibits checkpoint maintenance and homologous recombination repair. EMBO Rep. 17:94–109. 2016. View Article : Google Scholar : PubMed/NCBI

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, et al: Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 31:286–299. 2017. View Article : Google Scholar : PubMed/NCBI

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, et al: DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 22:1488–1495. 2016. View Article : Google Scholar : PubMed/NCBI

Picco G, Cattaneo CM, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Rodríguez IS, Cancelliere C, Banerjee R, et al: Werner helicase is a synthetic-lethal vulnerability in mismatch repair-deficient colorectal cancer refractory to targeted therapies, chemotherapy, and immunotherapy. Cancer Discov. 11:1923–1937. 2021. View Article : Google Scholar : PubMed/NCBI

Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, et al: Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 552:116–120. 2017. View Article : Google Scholar : PubMed/NCBI

Gay CM, Parseghian CM and Byers LA: This is our cells under pressure: Decreased DNA damage repair in response to targeted therapies facilitates the emergence of drug-resistant clones. Cancer Cell. 37:5–7. 2020. View Article : Google Scholar : PubMed/NCBI

Guo W, Qiao T, Dong B, Li T, Liu Q and Xu X: The effect of hypoxia-induced exosomes on anti-tumor immunity and its implication for immunotherapy. Front Immunol. 13:9159852022. View Article : Google Scholar : PubMed/NCBI

Qin Y, Liu HJ, Li M, Zhai DH, Tang YH, Yang L, Qiao KL, Yang JH, Zhong WL, Zhang Q, et al: Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway. EBioMedicine. 38:25–36. 2018. View Article : Google Scholar : PubMed/NCBI

Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D and Fu L: Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. Mol Cancer. 20:172021. View Article : Google Scholar : PubMed/NCBI

Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, et al: Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget. 7:20054–20067. 2016. View Article : Google Scholar : PubMed/NCBI

Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK and Andreeff M: An ARC-regulated IL1β/Cox-2/PGE2/β-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML. Cancer Res. 79:1165–1177. 2019. View Article : Google Scholar : PubMed/NCBI

Chambers LM, Esakov Rhoades EL, Bharti R, Braley C, Tewari S, Trestan L, Alali Z, Bayik D, Lathia JD, Sangwan N, et al: Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer. Cancer Res. 82:4654–4669. 2022. View Article : Google Scholar : PubMed/NCBI

Johnston CD and Bullman S: Bacteria-derived L-lactate fuels cervical cancer chemoradiotherapy resistance. Trends Cancer. 10:97–99. 2024. View Article : Google Scholar : PubMed/NCBI

Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin XL, Zhang L, Li CS, Qian Y, Xu PP, Leng XX, et al: Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 31:781–797.e9. 2023. View Article : Google Scholar : PubMed/NCBI

Lin ZZ, Hu MC, Hsu C, Wu YM, Lu YS, Ho JA, Yeh SH, Chen PJ and Cheng AL: Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Cancer Lett. 556:2160632023. View Article : Google Scholar : PubMed/NCBI

Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A and Pathak C: Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken). 5:e12912022. View Article : Google Scholar : PubMed/NCBI

Freter R, Falletta P, Omrani O, Rasa M, Herbert K, Annunziata F, Minetti A, Krepelova A, Adam L, Käppel S, et al: Establishment of a fluorescent reporter of RNA-polymerase II activity to identify dormant cells. Nat Commun. 12:33182021. View Article : Google Scholar : PubMed/NCBI

Summers MA, McDonald MM and Croucher PI: Cancer cell dormancy in metastasis. Cold Spring Harb Perspect Med. 10:a0375562020. View Article : Google Scholar : PubMed/NCBI

Yeh AC and Ramaswamy S: Mechanisms of cancer cell dormancy-another hallmark of cancer? Cancer Res. 75:5014–5022. 2015. View Article : Google Scholar : PubMed/NCBI

Pajic M, Blatter S, Guyader C, Gonggrijp M, Kersbergen A, Küçükosmanoğlu A, Sol W, Drost R, Jonkers J, Borst P and Rottenberg S: Selected alkylating agents can overcome drug tolerance of G₀-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice. Clin Cancer Res. 23:7020–7033. 2017. View Article : Google Scholar : PubMed/NCBI

Badia-Ramentol J, Linares J, Gómez-Llonin A and Calon A: Minimal residual disease, metastasis and immunity. Biomolecules. 11:1302021. View Article : Google Scholar : PubMed/NCBI

Rehman SK, Haynes J, Collignon E, Brown KR, Wang Y, Nixon AML, Bruce JP, Wintersinger JA, Singh Mer A, Lo EBL, et al: Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell. 184:226–242.e21. 2021. View Article : Google Scholar : PubMed/NCBI

Cackowski FC and Heath EI: Prostate cancer dormancy and recurrence. Cancer Lett. 524:103–108. 2022. View Article : Google Scholar : PubMed/NCBI

Akkoc Y, Peker N, Akcay A and Gozuacik D: Autophagy and cancer dormancy. Front Oncol. 11:6270232021. View Article : Google Scholar : PubMed/NCBI

Damen MPF, van Rheenen J and Scheele CLGJ: Targeting dormant tumor cells to prevent cancer recurrence. FEBS J. 288:6286–6303. 2021. View Article : Google Scholar : PubMed/NCBI

Lee J, Kim SH and Kang BJ: Prognostic factors of disease recurrence in breast cancer using quantitative and qualitative magnetic resonance imaging (MRI) parameters. Sci Rep. 10:75982020. View Article : Google Scholar : PubMed/NCBI

Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, et al: AMPK activation by metformin promotes survival of dormant ER⁺ breast cancer cells. Clin Cancer Res. 26:3707–3719. 2020. View Article : Google Scholar : PubMed/NCBI

Zhu X, Wang F, Wu X, Li Z, Wang Z, Ren X, Zhou Y, Song F, Liang Y, Zeng Z, et al: FBX8 promotes metastatic dormancy of colorectal cancer in liver. Cell Death Dis. 11:6222020. View Article : Google Scholar : PubMed/NCBI

Quayle LA, Spicer A, Ottewell PD and Holen I: Transcriptomic profiling reveals novel candidate genes and signalling programs in breast cancer quiescence and dormancy. Cancers (Basel). 13:39222021. View Article : Google Scholar : PubMed/NCBI

Preciado J, Lam T, Azarin SM, Lou E and Aksan A: Induction of dormancy by confinement: An agarose-silica biomaterial for isolating and analyzing dormant cancer cells. J Biomed Mater Res B Appl Biomater. 109:2117–2130. 2021. View Article : Google Scholar : PubMed/NCBI

Drescher F, Juárez P, Arellano DL, Serafín-Higuera N, Olvera-Rodriguez F, Jiménez S, Licea-Navarro AF and Fournier PG: TIE2 induces breast cancer cell dormancy and inhibits the development of osteolytic bone metastases. Cancers (Basel). 12:8682020. View Article : Google Scholar : PubMed/NCBI

Cho J, Min HY, Lee HJ, Hyun SY, Sim JY, Noh M, Hwang SJ, Park SH, Boo HJ, Lee HJ, et al: RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. J Clin Invest. 131:e1719012021. View Article : Google Scholar

Clark AM, Heusey HL, Griffith LG, Lauffenburger DA and Wells A: IP-10 (CXCL10) can trigger emergence of dormant breast cancer cells in a metastatic liver microenvironment. Front Oncol. 11:6761352021. View Article : Google Scholar : PubMed/NCBI

Yu Z, Zhou R, Zhao Y, Pan Y, Liang H, Zhang JS, Tai S, Jin L and Teng CB: Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death. Cell Prolif. 52:e125682019. View Article : Google Scholar : PubMed/NCBI

Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, et al: Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 375:1254–1261. 2022. View Article : Google Scholar : PubMed/NCBI

Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, et al: Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. 37:104–122.e12. 2020. View Article : Google Scholar : PubMed/NCBI

Dhimolea E, de Matos Simoes R, Kansara D, Al'Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P, Shirasaki R, et al: An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell. 39:240–256.e11. 2021. View Article : Google Scholar : PubMed/NCBI

Hussein AM, Wang Y, Mathieu J, Margaretha L, Song C, Jones DC, Cavanaugh C, Miklas JW, Mahen E, Showalter MR, et al: Metabolic control over mTOR-dependent diapause-like state. Dev Cell. 52:236–250. e72020. View Article : Google Scholar : PubMed/NCBI

Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, et al: The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 118:3917–3929. 2008.PubMed/NCBI

Anlaş AA and Nelson CM: Soft microenvironments induce chemoresistance by increasing autophagy downstream of integrin-linked kinase. Cancer Res. 80:4103–4113. 2020. View Article : Google Scholar : PubMed/NCBI

Tallón de Lara P, Castañón H, Vermeer M, Núñez N, Silina K, Sobottka B, Urdinez J, Cecconi V, Yagita H, Movahedian Attar F, et al: CD39⁺PD-1⁺CD8⁺ T cells mediate metastatic dormancy in breast cancer. Nat Commun. 12:7692021. View Article : Google Scholar : PubMed/NCBI

Ju S, Wang F, Wang Y and Ju S: CSN8 is a key regulator in hypoxia-induced epithelial-mesenchymal transition and dormancy of colorectal cancer cells. Mol Cancer. 19:1682020. View Article : Google Scholar : PubMed/NCBI

Chen ML, Sun A, Cao W, Eliason A, Mendez KM, Getzler AJ, Tsuda S, Diao H, Mukori C, Bruno NE, et al: Physiological expression and function of the MDR1 transporter in cytotoxic T lymphocytes. J Exp Med. 217:e201913882020. View Article : Google Scholar : PubMed/NCBI

Mu QG, Lin G, Jeon M, Wang H, Chang FC, Revia RA, Yu J and Zhang M: Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer. Mater Today (Kidlington). 50:149–169. 2021. View Article : Google Scholar : PubMed/NCBI

Li S, Li C, Jin S, Liu J, Xue X, Eltahan AS, Sun J, Tan J, Dong J and Liang XJ: Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo. Biomaterials. 144:119–129. 2017. View Article : Google Scholar : PubMed/NCBI

Ling X, Chen X, Riddell IA, Tao W, Wang J, Hollett G, Lippard SJ, Farokhzad OC, Shi J and Wu J: Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance. Nano Lett. 18:4618–4625. 2018. View Article : Google Scholar : PubMed/NCBI

Wu F, Du Y, Yang J, Shao B, Mi Z, Yao Y, Cui Y, He F, Zhang Y and Yang P: Peroxidase-like active nanomedicine with dual glutathione depletion property to restore oxaliplatin chemosensitivity and promote programmed cell death. ACS Nano. 16:3647–3663. 2022. View Article : Google Scholar : PubMed/NCBI